Aardvark Therapeutics (AARD) Sees Major Rally Potential as Analyst Price Target Climbs 127% Above Current Levels

metaverse_hermit · 2025-12-31T16:05:28+00:00

Aardvark Therapeutics is garnering significant interest from major investment firms, with Oppenheimer giving an "Outperform" rating and a price target suggesting a 127.45% potential gain. Institutional investments have also risen, indicating increasing confidence in the company's prospects.

metaverse_hermit

2025-12-31 16:05:28

Abstract generation in progress

Wall Street’s Bold Forecast on AARD

Aardvark Therapeutics is attracting serious attention from major investment firms. Oppenheimer has recently issued an “Outperform” rating on the stock, signaling confidence in its near-term prospects. What’s more compelling is the analyst price target: at $33.09 per share, the consensus forecast suggests a potential gain of 127.45% from the current market price of $14.55/share. Price targets among analysts range widely, from as low as $18.18 to as high as $52.50, reflecting varying degrees of conviction about the company’s upside.

The projected annual non-GAAP earnings per share stands at -2.94, indicating the company remains in a development or early commercialization phase—a common profile for biotech firms with significant growth potential.

Institutional Money Moving Into AARD

The fund positioning around Aardvark Therapeutics has shifted noticeably. A total of 110 funds and institutions currently hold positions in AARD, representing a 29.41% quarter-over-quarter increase of 25 new owners. Institutions collectively own 9,631K shares, up 5.56% over the last three months. The average portfolio allocation across all institutional holders is 0.09%, which has grown 49.45%—a sign that money managers are increasing their conviction levels.

Major Shareholders and Their Recent Moves

Leading the pack is Decheng Capital with 3,917K shares (17.99% ownership). The position remained flat compared to the prior quarter.

Citadel Advisors maintains a substantial 1,360K share stake (6.25% ownership), up from 1,284K shares previously—a 5.60% increase. However, the firm trimmed its overall portfolio weight in AARD by 8.74%, suggesting a selective approach to the position.

Laurion Capital Management holds 1,050K shares (4.82% ownership), an uptick from 989K shares in the prior period, representing a 5.78% gain. Like Citadel, Laurion slightly reduced its portfolio allocation in AARD by 0.62%.

Adage Capital Partners Gp, L.l.c. doubled down aggressively with 350K shares (1.61% ownership), versus 175K shares previously—a remarkable 50.00% increase. The firm also boosted its portfolio weighting in AARD by 84.79%.

Perhaps most striking is VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, which surged its holding from just 34K shares to 337K shares—an 89.87% jump representing 1.55% of the company. The portfolio allocation skyrocketed by 1,486.09%, indicating massive relative buying pressure within this index fund.

What It Means

The convergence of a prominent analyst upgrade, a triple-digit price target, and accelerating institutional investment creates a compelling narrative around Aardvark Therapeutics. Whether AARD can deliver on Wall Street’s optimistic projections remains to be seen, but the directional shift in smart money positioning warrants attention from growth-focused investors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.